Understanding what patients want from NSCLC treatment monitoring

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational qualitative study uses focus group discussions to explore how NSCLC patients experience treatment across physical, psychological, and social dimensions, and to capture preferences for symptom monitoring by clinicians. The research builds on a literature review and informal discussions with clinicians and patient representatives to identify priorities and potential gaps. Four focus groups with patients, two with caregivers, and one with clinicians will be conducted at the European Institute of Oncology to elicit important attributes related to patient-reported outcomes, patient-reported experience measures, and clinical outcomes. The study aims to generate a comprehensive view of monitoring needs to inform patient-centered care in NSCLC treatment.

Why it matters

Who can join: the full rules

Patients' inclusion Criteria

* Adults (≥ 18);
* Histological or cytological diagnosis of NSCLC stage II or III or IV as classified by the UICC TNM VIII Edition;
* Patients who underwent surgery for Non-Small Cell Lung Cancer diagnosis (primary cancer) and already started targeted therapy or immunotherapy or chemo-immunotherapy combination;
* Patients diagnosed with Non-Small Cell Lung Cancer (primary cancer) not treated with surgery but candidates for targeted therapy or immunotherapy or chemo-immunotherapy combination.

Patients' exclusion Criteria

* Patients who have had pneumonectomy (whole lung removal);
* Severe psychiatric illness or cognitive impairment or inadequate verbal skills that may render them incapable of informed consent (as evaluated by the clinician);
* Inability to understand study materials (as evaluated by the clinician);
* Physical or psychological impairment that prohibits their participation in focus group (as evaluated by the clinician);
* Patients unable to use DHT or mobile applications;
* Patients unable to speak Italian.

Caregivers' inclusion criteria:

* Adults (≥ 18);
* Taking care of the patients recruited for the FGD.

Caregivers' exclusion criteria:

* Severe psychiatric illness or cognitive impairment or inadequate verbal skills that may render them incapable of informed consent.
* Inability to understand study materials;
* Physical or psychological impairment that prohibits their participation in focus group;
* Unable to use DHT or mobile applications.
* Unable to speak Italian.

Clinicians' inclusion criteria:

* Adults (≥ 18);
* Treating the patients recruited for the FGD; • Have been working for at least one yea in the Thoracic Surgery Division of the IEO.

Clinicians' exclusion criteria:

* Severe psychiatric illness or cognitive impairment or inadequate verbal skills that may render them incapable of informed consent.
* Inability to understand study materials;
* Physical or psychological impairment that prohibits their participation in focus group;
* Unable to use DHT or mobile applications.
* Unable to speak Italian.

Where it's running

• European institute of oncology
  Milan, mI, Italy Recruiting

Study contacts

• Study coordinator: Gabriella Pravettoni
• Email: gabriella.pravettoni@ieo.it
• Phone: 00390223901

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC

  This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07841249

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• NUT Project: Nutritional Support in Thoracic Cancer

  We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.

  Recruiting Casa di Cura Dott. Pederzoli · Peschiera del Garda, Verona · NCT07817329

• Single-Port Robotic Lobectomy for Early-Stage NSCLC

  This study tests the safety and outcomes of using the da Vinci Single-Port system for lobectomy and lymph node dissection in people with early-stage non-small cell lung cancer.

  Recruiting European Institute of Oncology · Milan, Mi · NCT07790406

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.